Abstract
Depression during midlife years may lead to significant sleep disturbances and adversely impact quality of life (QOL). In this report, we examined the effects of treatment with quetiapine extended release (XR), 150–300 mg/day, on sleep and QOL in 23 midlife women with major depressive disorder (MDD). Quetiapine XR improved subjective sleep distress, overall sleep parameters, and sleep-related QOL, ultimately leading to significant improvement in menopause-related QOL. While larger, controlled trials are still awaited, these preliminary results are encouraging and suggest that quetiapine XR may be a useful tool in treating symptomatic midlife women with MDD.
This is a preview of subscription content, log in via an institution to check access.
References
Bolge SC, Balkrishnan R, Kannan H, Seal B, Drake CL (2010) Burden associated with chronic sleep maintenance insomnia characterized by nighttime awakenings among women with menopausal symptoms. Menopause 17:80–86
Diehr PH, Derleth AM, McKenna SP, Martin ML, Bushnell DM et al (2006) Synchrony of change in depressive symptoms, health status, and quality of life in persons with clinical depression. Health Qual Life Outcomes 4:27
Greene JG (1998) Constructing a standard climacteric scale. Maturitas 29:25–31
Harvey AG (2011) Sleep and circadian functioning: critical mechanisms in the mood disorders? Annu Rev Clin Psychol 7:297–319
Hilditch JR, Lewis J, Peter A, van Maris B, Ross A et al (1996) A menopause-specific quality of life questionnaire: development and psychometric properties. Maturitas 24:161–175
Ishak WW, Ha K, Kapitanski N, Bagot K, Fathy H et al (2011) The impact of psychotherapy, pharmacotherapy, and their combination on quality of life in depression. Harv Rev Psychiatry 19:277–289
Joffe H, Soares CN, Petrillo LF, Viguera AC, Somley BL et al (2007) Treatment of depression and menopause-related symptoms with the serotonin-norepinephrine reuptake inhibitor duloxetine. J Clin Psychiatry 68:943–950
Moul DE, Pilkonis PA, Miewald JM, Carey TJ, Buysse DJ (2002) Preliminary study of the test–retest reliability and concurrent validities of the Pittsburgh Insomnia Rating Scale (PIRS). Sleep 25:A246–A247
Papakostas GI, Petersen T, Mahal Y, Mischoulon D, Nierenberg AA, Fava M (2004) Quality of life assessments in major depressive disorder: a review of the literature. Gen Hosp Psychiatry 26:13–17
Perlis ML, Giles DE, Buysse DJ, Tu X, Kupfer DJ (1997) Self-reported sleep disturbance as a prodromal symptom in recurrent depression. J Affect Disord 42:209–212
Pillai V, Kalmbach DA, Ciesla JA (2011) A meta-analysis of electroencephalographic sleep in depression: evidence for genetic biomarkers. Biol Psychiatry 70:912–919
Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J (1998) The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59(20):22–33, quiz 4-57
Soares CN (2005) Insomnia in women: an overlooked epidemic? Arch Women Ment Health 8:205–213
Soares CN, Arsenio H, Joffe H, Bankier B, Cassano P et al (2006) Escitalopram versus ethinyl estradiol and norethindrone acetate for symptomatic peri- and postmenopausal women: impact on depression, vasomotor symptoms, sleep, and quality of life. Menopause 13:780–786
Soares CN, Frey BN, Haber E, Steiner M (2010) A pilot, 8-week, placebo lead-in trial of quetiapine extended release for depression in midlife women: impact on mood and menopause-related symptoms. J Clin Psychopharmacol 30:612–615
Soares CN, Murray BJ (2006) Sleep disorders in women: clinical evidence and treatment strategies. Psychiatr Clin North Am 29:1095–1113, abstract xi
Soares CN, Zitek B (2008) Reproductive hormone sensitivity and risk for depression across the female life cycle: a continuum of vulnerability? J Psychiatry Neurosci 33:331–343
Soules MR, Sherman S, Parrott E, Rebar R, Santoro N et al (2001) Executive summary: Stages of Reproductive Aging Workshop (STRAW). Fertil Steril 76:874–878
Van Londen L, Molenaar RP, Goekoop JG, Zwinderman AH, Rooijmans HG (1998) Three- to 5-year prospective follow-up of outcome in major depression. Psychol Med 28:731–735
Williams RE, Levine KB, Kalilani L, Lewis J, Clark RV (2009) Menopause-specific questionnaire assessment in US population-based study shows negative impact on health-related quality of life. Maturitas 62:153–159
Conflict of interest
This study was supported through an investigator-initiated research grant from AstraZeneca (Dr. Soares) and by the CIHR Rx & D Research Fellowship Program (Dr. Frey) (Clinical Trial Registration: ClinicalTrials.gov, www.clinicaltrials.gov, NCT00723970). Dr. Frey has received grant/research support from Alternative Funding Plan Innovations Award (AFP, McMaster University), CIHR, Hamilton Health Sciences Foundation, Stanley Medical Research Foundation, Eli Lilly, Pfizer, and Bristol-Myers Squibb; he has received honoraria from AstraZeneca, Lundbeck and Pfizer. Dr. Steiner has received research grants/funding from CIHR, Pfizer, Eli Lilly, and Lundbeck; has served as a consultant for AstraZeneca, Azevan, Bayer Canada, Servier, and Lundbeck; and has received honoraria from the Society for Women’s Health Research and AstraZeneca. Dr. Soares has received grant/research support from Alternative Funding Plan Innovations Award (AFP, McMaster University), CIHR, NARSAD Brain and Behavior Foundation, Eli Lilly, Pfizer and Lundbeck; has received honoraria from AstraZeneca, Noven Pharmaceuticals, Bristol-Myers Squibb, Lundbeck and Pfizer. E. Haber and G. Mendes had no potential conflicts to disclose.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Frey, B.N., Haber, E., Mendes, G.C.D. et al. Effects of quetiapine extended release on sleep and quality of life in midlife women with major depressive disorder. Arch Womens Ment Health 16, 83–85 (2013). https://doi.org/10.1007/s00737-012-0314-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00737-012-0314-y